EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
Vivos Therapeutics, Inc. (VVOS) had EBIT Margin of -129.91% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$3.02M |
|
$-3.86M |
|
$1.51M |
|
$1.51M |
|
$6.93M |
|
$-3.92M |
|
$0.05M |
|
$-3.86M |
|
$-3.86M |
|
$-3.86M |
|
$-3.86M |
|
$-3.86M |
|
$-3.86M |
|
$-3.92M |
|
$-3.74M |
|
8.60M |
|
8.60M |
|
$-0.45 |
|
$-0.45 |
|
| Balance Sheet Financials | |
$3.61M |
|
$3.31M |
|
$7.67M |
|
$11.28M |
|
$4.70M |
|
-- |
|
$2.17M |
|
$6.88M |
|
$4.41M |
|
$1.21M |
|
$4.41M |
|
5.89M |
|
| Cash Flow Statement Financials | |
$-3.80M |
|
$-0.12M |
|
$0.00M |
|
$6.26M |
|
$2.34M |
|
$-3.92M |
|
$0.32M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.77 |
|
-- |
|
-- |
|
-- |
|
-- |
|
50.03% |
|
-129.91% |
|
|
EBIT Margin |
-129.91% |
-- |
|
-128.12% |
|
-128.12% |
|
$-3.92M |
|
-- |
|
-- |
|
-- |
|
0.27 |
|
-- |
|
4.20 |
|
21.43 |
|
-87.68% |
|
-320.40% |
|
-34.25% |
|
-87.68% |
|
$0.75 |
|
$-0.46 |
|
$-0.44 |
|